Citizens JMP Securities Upgrades Rezolute Following Late-Stage Trial Update
Rezolute (RZLT) saw its stock rise for the third consecutive session after Citizens JMP Securities upgraded it, citing a recent late-stage trial update on its lead asset, ersodetug. The upgrade has contributed to increased investor interest in the rare-disease drug developer.
Topics: broker upgrades clinical trials pharmaceuticals rare diseases